<DOC>
	<DOC>NCT01326962</DOC>
	<brief_summary>This open-label, single arm study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs) or anti-TNF. Patients will receive RoActemra/Actemra at a dose of 8 mg/kg (max 800 mg) intravenously every 4 weeks for a total of 6 infusions. Non-biologic DMARD therapy may be continued throughout the study. Anticipated time on study treatment is 24 weeks.</brief_summary>
	<brief_title>A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Active moderate to severe rheumatoid arthritis of &gt;/= 6 months duration &gt;/=1 nonbiologic DMARD and/or antiTNF therapy at stable dose for &gt;/=8 weeks at any time prior to study treatment Inadequate clinical response to nonbiologic DMARD or antiTNF therapy Oral corticosteroids must be at stable dose for at least 25 out of 28 days prior to first dose of study drug Pregnant or lactating women Major surgery (including joint surgery) within 8 weeks prior to screening or major surgery planned within 6 months of enrolment Rheumatic autoimmune disease other than RA Functional class IV (ACR classification) Prior history of or current joint disease other than RA Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline Previous treatment with RoActemra/Actemra Known active current or history of recurrent infection History of or currently active primary or secondary immunodeficiency Active tuberculosis requiring treatment within the previous 3 years Positive for HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>